FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/03/2026
Voltar para busca
Dado oficial do USPTO
ANGICYTE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
ANGICYTE
ST13
US500000079399244Classe
1, 5, 10, 42, 44
Pedido
79399244
Registro
7838997
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
28
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 10, 42, 44
Data de depósito
04/03/2024
Data de registro
24/06/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
24/06/2025
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
24
Localização do titular
GB
Examinador
JANSON, ANDREW KYLE
Unidade examinadora
L50
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
VASCVERSA LIMITED
Representantes
Usha Menon D'Ambrosio & Menon, PLLC
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 10Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Stem cells for research purposes; stem cells for scientific purposes; chemicals for use in manufacturing pharmaceuticals; reagents for research purposes; reagents for medical research; reagents for scientific purposes; diagnostic reagents for scientific or research use; cell culture reagents for scientific and research use; blood culture media for scientific use
Classe 5
Pharmaceutical preparations for the treatment of ischemic diseases; Drugs for medical purposespharmaceutical preparations for the treatment of ischemic diseases; Pharmaceutical preparations containing stem cells for the treatment of ischemic diseases and stimulation of vascular regenerationblood vessel repairtissue revitalization; Stem cells for medical purposes; cells for medical use; cell growth media for growing cells for medical use; living cells for medical use; cellular function activating agents for medical purposes; Vaccines; Reagents for medical use; medical diagnostic reagents
Classe 10
Medical devices for the treatment of ischemic diseases and stimulation of vascular regenerationblood vessel repairtissue revitalization; Medical apparatus and instruments for the treatment of ischemic diseases and stimulation of vascular regenerationblood vessel repairtissue revitalization; Apparatus for the regeneration of stem cells for medical purposes; medical devices and apparatus for vascular regeneration and repair in the treatment of ischemic diseases; Medical devices and apparatus for cell therapy for the treatment of ischemic diseases and stimulation of vascular regenerationblood vessel repairtissue revitalization; Blood testing apparatus
Classe 42
Medical and pharmacological research services; Stem cell research; Scientific research services for others relating to the isolation and cultivation of human tissues and cells; Research in the field of cell engineering technology; Scientific and medical research in the field of vascular regeneration and repair; Research and development of medicines; Pharmaceutical drug development services; Drug discovery services; Development of pharmaceutical preparations and medicines; Development of stem and progenitor cell therapies and other cell therapies; Research and development services in the medical field of cell therapy; research and development services in the medical field of vascular regeneration and repair; Scientific research in the nature of conducting clinical trials for others; Blood analysis services for scientific research purposes
Classe 44
Regenerative medicine services; medical services; stem cell therapy services; cell therapy services; Stem cell therapy services for vascular regeneration and repair; cell therapy services relating to the generation of human vascular reparative cells; cell therapy services relating to the injectinggrafting or implanting of cells into patients; medical services relating to the removaltreatment and processing of cells; Medical services relating to the removaltreatment and processing of stem cells; Stem cell storagestem cell bank services; Cultured cell bank services for medical transplantation; medical laboratory services for the analysis of samples taken from patients; Medical analysis services for the diagnosis and treatment of persons; Services for the testing of bloodmedical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical services relating to the removaltreatment and processing of human blood
Publicações
Histórico de despachos e eventos da marca no USPTO.
28 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
19/02/2026
NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/02/2026
FICS
FINAL DISPOSITION NOTICE SENT TO IB
21/01/2026
FIMP
FINAL DISPOSITION PROCESSED
21/01/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
18/12/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/12/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
03/12/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
24/09/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/07/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
24/06/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
24/06/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/05/2025
PUBO
PUBLISHED FOR OPPOSITION
06/05/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
30/04/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/04/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
13/03/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/03/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/03/2025
RFNT
REFUSAL PROCESSED BY IB
12/10/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
21/09/2024
RFRR
REFUSAL PROCESSED BY MPU
20/09/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
19/09/2024
CNRT
NON-FINAL ACTION WRITTEN
18/09/2024
DOCK
ASSIGNED TO EXAMINER
18/09/2024
MAFR
APPLICATION FILING RECEIPT MAILED
11/07/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/07/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/07/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ANGICYTE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.